Otitopic is a clinical-stage company developing Asprihale, a proprietary dry powder formulation of aspirin, delivered via a portable dry powder inhaler. The active pharmaceutical ingredient is expected to enter the bloodstream faster than oral tablets at the time of myocardial infarction.
10390 Santa Monica Blvd #200
Phone / ContactT: +1 800 299 9047
Otitopic is a clinical-stage dry powder inhalation of aspirin company with a track record of success in pharmaceutical product drug delivery and drug device development. Asprihale is a proprietary dry powder inhalation of aspirin formulation delivered via portable dry powder inhaler that is expected to enter the bloodstream faster than oral tablets at the time of MI.
Otitopic is on track with Asprihale to file a US NDA for a novel drug device combination product in rescue management of suspected acute MI. Otitopic is committed to providing highrisk MI patients with a faster alternative for management of suspected MI. The company is currently assessing non small-cell lung cancer as an additional indication to the MI indication therapy.
Otitopic was founded in 2012 and is privately owned.